TLR4 and rosacea: Following combined treatment with TLR4 overexpression and the NF-κB signaling pathway inhibitor PDTC, TLR4 expression remained unaltered in rosacea-like cells, while the p-NF-κB/NF-κB was significantly reduced (Fig 5A).